Bioassay of XXXX for possible carcinogenicity.

@entity137 @entity19 @entity5 @entity400 @entity21093 @entity35
A bioassay of the carcinogenicity of technical-grade @entity21093 was conducted using Osborne-Mendel @entity35 and B6C3F1 @entity19 . The test material was administered in feed to groups of 50 @entity35 of each sex at either of two concentrations for 80 weeks, followed by 35 weeks of observation. Initial doses were not well tolerated; therefore, they were reduced during the study. The "time-weighted average doses" for @entity35 were 155 and 310 ppm for males and 192 and 384 ppm for females. All surviving @entity35 were killed between 113 and 115 weeks. @entity21093 was administered in feed to groups of 50 male and 50 female @entity19 at two concentrations. Female @entity19 received diets containing 200 and 500 ppm of @entity21093 for 80 weeks; male @entity19 received the same dosage. However, high-dose males were returned to the control diet at 60 weeks, and low-dose males at 69 weeks. All surviving @entity19 were killed between 93 and 94 weeks. @entity400 and hyperexcitability, both indications of @entity21093 @entity137 , were observed in the treated animals. However, it is considered that the low-dose group of @entity35 and both dose groups of @entity19 survived long enough to permit an evaluation of carcinogenicity. Pathologic evaluation revealed no statistically significant increase in @entity5 associated with @entity21093 treatment in either species of animal, and it is concluded that there was no carcinogenic effect under the conditions of the experiment.
